“At trial BioPoint alleged theft of more than 50 different so-called trade secrets, including the names and resumes of third-party consultants that were publicly available on Linked-In. The verdict slip, which Catapult objected to, did not ask the jury to identify the trade secrets that they found to have been misappropriated. Thus, there is no way of knowing what the jury found was the ‘trade secret’ that was misappropriated,” said Dana Zakarian, a partner at Smith Duggan Cornell & Gollub, who represents the defendants.